Eli Lilly, Chi-Med’s Elunate becomes first China-made cancer drug to win a key nodAllbiopro2018-09-06T02:16:53+09:009월 6th, 2018|
After snubbing Gilead, British cost watchdogs give thumbs-up to Novartis’ CAR-T KymriahAllbiopro2018-09-06T02:16:25+09:009월 6th, 2018|
No sweat? Dermira snags reps, sets price and plots branded ads for Qbrexza launchAllbiopro2018-09-06T02:15:56+09:009월 6th, 2018|
Otsuka’s dose-tracking digital pill charts its first course to market with MagellanAllbiopro2018-09-06T02:15:28+09:009월 6th, 2018|
Novo Nordisk’s Ozempic spends big on TV in August but still trails AbbVie, Pfizer big gunsAllbiopro2018-09-06T02:15:00+09:009월 6th, 2018|
Italian CDMO buys India API plant that supplies NovartisAllbiopro2018-09-06T02:14:32+09:009월 6th, 2018|
Startup Gossamer Bio poaches Bristol-Myers Squibb executive as CSOAllbiopro2018-09-06T02:13:38+09:009월 6th, 2018|
Teva finally dumps laquinimod, ending failure-riddled sagaAllbiopro2018-09-06T02:13:11+09:009월 6th, 2018|
Ramaswamy loses another key executive as Fouse jumps ship to AgiosAllbiopro2018-09-06T02:12:17+09:009월 6th, 2018|
PhaseBio nets $34M to advance Brilinta reversal agent, PAH drugAllbiopro2018-09-06T02:11:24+09:009월 6th, 2018|
Sean Harper and Beth Seidenberg unite to run $320M VC fundAllbiopro2018-09-06T02:10:57+09:009월 6th, 2018|
With promising data, ProQR Therapeutics’ RNA-based eye drug heads to phase 3Allbiopro2018-09-06T02:10:31+09:009월 6th, 2018|
B Cells Among Factors Leading to Brain Lesions in Multiple SclerosisAllbiopro2018-09-06T02:09:38+09:009월 6th, 2018|
